According to TipRanks, Benjamin is an analyst with an average return of -10.3% and a 33.50% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Spectrum Pharmaceuticals, and Allogene Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Compugen with a $6.00 average price target, which is a 488.24% upside from current levels. In a report released on November 15, Oppenheimer also maintained a Buy rating on the stock with a $8.00 price target.
CGEN market cap is currently $88.36M and has a P/E ratio of -2.24.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.
Read More on CGEN: